NYSE · Healthcare · Analyst ratings
Eli Lilly and Company sell-side coverage.
Wall Street consensus, the buy/hold/sell mix, and 12-month price targets for LLY — 39 analysts in the latest TECHi feed.
Consensus
Buy
Median target
—
High target
—
Low target
—
Recommendation mix
Buy & Strong Buy
30/ 39
77% of coverage
Hold
8/ 39
21% of coverage
Sell & Strong Sell
1/ 39
3% of coverage
Consensus read
Lopsided bullish on LLY.
30 of 39 (77%) carry a Buy or Strong Buy. The consensus target of — implies — from the live tape. Watch for revisions in the next 30 days — a bullish skew that's still revising up is the highest-conviction signal; a bullish skew that's flat-to-down on revisions is consensus catching up to a stock that's run.
Deeper view
TECHi forecast desk.
For the bull / base / bear scenarios, the TECHi-issued price target, and per-author accuracy on LLY, see the LLY forecast page.
Frequently asked
Common questions.
What is the analyst consensus on LLY?
The LLY Analysis page tracks the sell-side consensus rating (Strong Buy / Buy / Hold / Sell / Strong Sell), the recommendation mix, and the median + average price targets for Eli Lilly and Company updated weekly.
What is LLY's 12-month price target?
Consensus, median, low, and high 12-month price targets for Eli Lilly and Company are displayed on the Analysis page with implied upside / downside vs the live LLY quote.
When does Eli Lilly and Company report earnings next?
Eli Lilly and Company's next scheduled earnings date — and the analyst EPS / revenue estimates for that quarter — appear at the top of the LLY Analysis page; surprise history is plotted underneath.
Where can I see TECHi analyst research on LLY?
TECHi's own analyst notes on Eli Lilly and Company (when published) appear in a dedicated card below the consensus block, with deep links to the full research report.